SEL-120

Following an analysis of Company resources and positive data in r/r AML, a population of high unmet medical need, Ryvu is prioritizing rapid development of romaciclib in AML. Updated clinical data from the Phase II RIVER-81 and POTAMI-61 studies will be presented at EHA 2026 (June 11-14, Stockholm). The Company signed the PERO grant agreement with the National Centre for Research and Development (NCBR), securing PLN 20.0 million in non-dilutive funding for an innovative oncology target validation platform. Total operating revenues in Q1 2026 amounted to €5.1 million, compared to €5.0 million for the same period in 2025. EBITDA loss was €2.4 million, compared to €8.4 million in the previous year. As of May 15, 2026, Ryvu’s cash position was €17.6 million. The Company has also secured approximately €20.6 million in non-dilutive grant funding. Krakow, Poland – May 21, 2026 – Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, today reported financial results for the first quarter, ended March 31, 2026. Pawel Przewiezlikowski, co-founder and Chief Executive Officer of Ryvu Therapeutics, said: Clinical results in RIVER-81 and POTAMI-61 Phase II studies support romaciclib’s further development both in acute myeloid leukemia and myelofibrosis. Based on resources and clinical data generated so far, we decided to prioritize the AML development path by enrolling approximately 30 additional patients in RIVER-81. Alongside romaciclib clinical development, we have demonstrated good results in our early-stage programs, including RVU305, our potentially best-in-class MTA-cooperative PRMT5 inhibitor and ONCO Prime platform. Projects developed in cooperation with our partners are progressing, with potentially important milestones ahead. Q1 2026 SUMMARY AND RECENT CORPORATE EVENTS Romaciclib (RVU120) clinical development plan progress Ryvu continues to advance the clinical development of romaciclib, a first-in-class selective CDK8/CDK19 inhibitor, across hematologic malignancies. Current data support continued development of romaciclib in acute myeloid leukemia (AML) and myelofibrosis (MF). With the particularly strong data in relapsed/refractory (r/r) AML, near-term priorities will focus on development in AML, where the high unmet medical need could lead to an accelerated approval path. Ryvu generated further clinical insights and will present updated clinical data from the RIVER-81 and POTAMI-61 studies at the European Hematology Association (EHA) Congress 2026 (June 11-14, Stockholm, Sweden). Based on available abstracts: RIVER-81: Romaciclib combined with venetoclax (VEN) shows encouraging anti-leukemic activity, including durable responses, in patients with r/r AML after VEN-based therapy failure. These results support further clinical development at the selected dose. POTAMI-61: Romaciclib demonstrates a favorable safety profile and clinical activity in MF, both as monotherapy and in combination with ruxolitinib. The observed spleen volume reductions and hematologic tolerability support continued clinical evaluation. On May 20, following the analysis of resources and clinical data generated so far, Ryvu decided to prioritize RIVER-81 study by enrolling approximately 30 additional patients. As part of resource prioritization, the Company decided to close the POTAMI-61 study (ongoing patients will continue to receive treatment in a new roll-over study ROVER-01). Ryvu retains the option to resume a modified MF development program. This approach is intended to preserve strategic optionality for romaciclib while, in the short term, focusing resources on the clinical dataset that is expected to be most relevant for potential development partners. New preclinical data for the ONCO Prime platform were presented at the AACR Annual Meeting 2026. Ryvu’s integrated precision oncology discovery platform leveraging patient-driven models, engineered systems, and high-throughput CRISPR/omics analytics, enables the identification of novel synthetic lethal vulnerabilities in genetically stratified colorectal cancer models, including proof-of-concept validation using a clinically approved drug. This establishes a scalable platform for drug discovery programs and strategic partnerships built on ONCO Prime’s ability to bridge functional genomics with therapeutic development. Extension of the research collaboration with BioNTech: on March 16, 2026, Ryvu reported that it amended its research collaboration and exclusive license option agreement with BioNTech, originally disclosed in November 2022. Under the amendment, the parties agreed to extend their research collaboration by an additional period of one year until November 2028. Grant funding for the PERO project: on March 11, 2026, the Company signed a grant agreement with the National Centre for Research and Development (in Polish: Narodowe Centrum Badań i Rozwoju; NCBR) for the PERO (“Predictive Engineering for Rational Oncology”) project. The objective of PERO is to establish an innovative technological platform for the functional validation of structural protein pockets of potential therapeutic targets in oncology. The project addresses a significant technological gap by enabling an in-depth, currently unavailable level of functional target validation based on integrated genomic, structural, and pharmacological data. The funding, PLN 20.0 million of a PLN 32.4 million project, will significantly fund the development of an innovative platform for functional target validation in oncology. Ryvu continues to advance partnerships with Menarini Group, BioNTech, and Exelixis, under which the Company is fully reimbursed for its expenses and has the potential to receive multiple financial milestones. KEY UPCOMING INDUSTRY AND INVESTOR EVENTS Ryvu will host partnering and investor meetings at the following conferences: ASCO Annual Meeting (Chicago, IL), May 29 to June 2 EHA Annual Congress (Stockholm, Sweden), June 12-15 BIO International Convention (San Diego, CA), June 22-25 Q1 2026 FINANCIAL UPDATE Cash Position – On May 15, 2026, Ryvu Therapeutics held €17.6 million in cash, cash equivalents and investment funds. In addition, the Company has secured approximately €20.6 million in non-dilutive grant funding. Operating Revenues – In Q1 2026, Ryvu recognized total operating revenues (including grants) of €5.1 million, compared with €5.0 million in Q1 2025. Operating costs, related primarily to research and development expenditures, excluding the valuation of NodThera shares and non-cash cost of valuation of the Incentive Program for Q1 2026, amounted to €8.0 million, compared to €11.4 million in Q1 2025. EBITDA result – EBITDA loss in Q1 2026 was €2.4 million, compared to €8.4 million in the previous year. Net Loss Attributable to Common Shareholders – In Q1 2026, the net loss attributable to common shareholders, excluding the non-cash cost of the Incentive Program, amounted to €2.9 million, compared to €5.8 million in the same period of the previous year. RYVU Therapeutics Leona Henryka Sternbacha 2 30-394 Kraków, Poland

Results presented at the American Society of Hematology (ASH) Annual Meeting in December 2025 confirmed the clinical activity of romaciclib (RVU120) in patients with relapsed/refractory acute myeloid leukemia (r/r AML), who have historically poor outcomes following venetoclax-based therapy. In the Phase II RIVER-81 study, complete and incomplete remission rates reached 43% in the 150 mg once-daily cohort, with a favorable safety profile. Romaciclib Phase II POTAMI-61 study in myelofibrosis (MF), which included patients previously exposed or refractory to JAK inhibitors, brought early signals of spleen volume reduction (SVR) and symptom improvement (total symptom score; TSS) without significant myelosuppression. SVR rate of at least 25% (SVR25) was met by 4 out of 14 evaluable patients (29%). At the same time SVR10 was achieved by 7 patients (50%). The Company is progressing research and clinical collaborations with BioNTech, Exelixis, and Menarini Group, as well as strengthening its long-term value drivers with progress in fully owned early pipeline projects. Total operating revenues for the full year 2025 were €20.7 million, compared to €23.7 million for the same period in 2024. EBITDA loss was reduced to €23.2 million, compared to €25.9 million in the previous year. For Q4 alone, those figures were €3.5 million and €8.8 million, respectively. As of March 9, 2026, Ryvu’s cash position was €20.7 million. In addition, Ryvu has secured approximately €20.9 million in non-dilutive grant funding. Krakow, Poland – March 19, 2026 – Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, reports its financials for the 2025 fiscal year and provides a corporate update. Pawel Przewiezlikowski, co-founder and Chief Executive Officer of Ryvu Therapeutics, said: – In 2025, we continued to focus on disciplined execution across our clinical programs while maintaining strict cost control. Our priority remains the efficient advancement of romaciclib (RVU120), for which we presented positive Phase II clinical data demonstrating efficacy in difficult-to-treat hematologic malignancies, including acute myeloid leukemia and myelofibrosis. At the same time, we continued to prepare RVU305 for clinical development and to advance multiple early pipeline programs. Thanks to ongoing partnerships and strategic reorganization implemented in Q1 2025, we are generating stable revenue streams and have significantly reduced operating costs. Importantly, we entered 2026 with new grant funding to support our preclinical discovery and research. Krzysztof Brzozka, Ph.D., Executive Vice President and Chief Scientific Officer, said: – Our discovery and research strategy continues to generate promising opportunities in precision oncology. The ONCO Prime platform remains a key engine of innovation, enabling the identification of novel precision oncology targets, including synthetic lethal approaches, in genetically defined cancers. In parallel, we continue to explore next-generation ADC payloads leveraging both synthetically lethal and immunocytotoxic mechanisms. Together with new projects – such as our PERO project (Predictive Engineering for Rational Oncology), which secured significant grant funding in March 2026 – these initiatives are designed to drive the development of future oncology therapies that address high unmet medical needs. 2025 SUMMARY AND RECENT CORPORATE EVENTS Romaciclib (RVU120) clinical development plan progress Ryvu continued to advance the clinical development of romaciclib (RVU120), a first-in-class selective CDK8/CDK19 inhibitor, across multiple hematologic malignancies. Current data support continued development of romaciclib in AML and MF, including further exploration of combination strategies. Throughout 2025, three Phase II studies continued as planned: RIVER-81 (combination with venetoclax in r/r AML), POTAMI-61 (monotherapy and combination with ruxolitinib in MF), and REMARK (monotherapy in LR-MDS; investigator-initiated trial). Ryvu generated further clinical insights and presented updated clinical data from the RIVER-81 and POTAMI-61 studies at the American Society of Hematology (ASH) Annual Meeting. RIVER-81 The Phase II RIVER-81 study evaluates the combination of romaciclib (RVU120), a selective CDK8/CDK19 inhibitor, with venetoclax (VEN) in unfit patients with r/r AML following frontline VEN plus hypomethylating agent (HMA) therapy, a patient population of high unmet need with no approved therapies. In the cohort testing romaciclib dose of 150 mg QD (once daily) and VEN 400 mg , 3 of 7 treated patients (43%) achieved CR/CRi (CRx) and 2 of 7 patients (28%) achieved CR. Overall, the mean duration of response at 150 mg QD was 141 days.   These data support expansion of the RIVER-81 study and present opportunities for investigation in additional AML settings, including the frontline setting. In January 2026, the U.S. Food and Drug Administration (FDA) held the Type C meeting requested by Ryvu. The FDA raised no objections to opening the expansion cohort in the United States with romaciclib at 150 mg QD in combination with VEN. POTAMI-61 The Phase II POTAMI-61 study evaluates romaciclib as monotherapy and in combination with ruxolitinib (RUX) in patients with MF who have failed or shown suboptimal response to JAK inhibitor therapy. Of the 14 patients evaluable for spleen volume evaluation at 12 weeks or more, 9 achieved spleen volume reduction, with 7 (50%) achieving at least SVR10 and 4 (29%) achieving SVR25 or better. One patient achieved a 59% reduction in spleen volume at week 36. Patients with a high-risk mutation in ASXL1 derived clinical benefit from romaciclib.  Significant and durable TSS improvement was achieved in patients in both cohorts.  These early data indicate that romaciclib is well tolerated and shows initial clinical activity, supporting continued evaluation of romaciclib as a potential therapeutic option for patients with MF. In September 2025, Ryvu announced the initiation of a collaboration with the Children’s Memorial Health Institute as part of the MEDWAY project, an investigator-initiated Phase I clinical study evaluating romaciclib in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma. FPFV (First Patient, First Visit) is expected in Q2 2026. Dapolsertib (MEN1703, SEL24): The JASPIS-01 Phase II study evaluates dapolsertib in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) as a monotherapy and in combination with glofitamab. The first patient was dosed in March 2025. JASPIS-01 is fully funded by the Menarini Group and operationally executed by Ryvu. RVU305: Ryvu continues development of RVU305, its potentially best-in-class brain-permeable, MTA-cooperative PRMT5 inhibitor, which is completing IND/CTA-enabling studies in preparation for clinical development. In October 2025, the Company presented preclinical data on RVU305 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, highlighting its brain-permeable profile and potential in MTAP-deleted cancers. Ryvu continues to advance its dual-pronged preclinical discovery and research strategy, focused on the ONCO Prime platform (novel small-molecule precision medicine, including synthetic lethality targets) and ADCs (antibody-drug conjugates) with novel payloads. Grant funding for the ADCraft project: on April 23, 2025, Ryvu announced signing a grant agreement with the Medical Research Agency (in Polish: Agencja Badań Medycznych, “MRA”) for the “ADCraft – next-generation small-molecule payloads for antibody-drug conjugates in oncology” project. The aim of the Project is to develop methods for discovering and testing a new generation of ADC payloads along with a portfolio of R&D activities focused on new therapeutic modalities used in oncology. The Company expects to receive PLN 9.9 million to support the project of a total net value of PLN 13.2 million. Grant funding for the PERO project: on March 11, 2026, the Company signed the grant agreement with the National Centre for Research and Development (in Polish: Narodowe Centrum Badan I Rozwoju; NCBR) for the PERO (“Predictive Engineering for Rational Oncology”) project. The objective of PERO is to establish an innovative technological platform for the functional validation of structural protein pockets of potential therapeutic targets in oncology. The project addresses a significant technological gap by enabling an in-depth, currently unavailable level of functional target validation based on integrated genomic, structural, and pharmacological data. The funding, PLN 20.0 million of a PLN 32.4 million project, will significantly fund the development of an innovative platform for functional target validation in oncology. Ryvu continues to advance partnerships with Menarini Group, BioNTech, and Exelixis, under which the Company is fully reimbursed for its expenses and has the potential to receive multiple financial milestones. Clinical collaboration with BioNTech: on September 2, 2025, Ryvu announced an expansion of its collaboration with BioNTech. Based on the new agreement, Ryvu supports BioNTech in accelerating site activation and patient enrollment for several of BioNTech’s priority oncology clinical programs in Poland, including indications such as lung, breast, and colorectal cancers. Extension of the research collaboration with BioNTech: on March 16, 2026, Ryvu informed about amending its research collaboration option exclusive license agreement with BioNTech, originally disclosed in November 2022. Under the amendment, the parties agreed to extend its research collaboration by an additional period of one year – until November 2028. KEY UPCOMING INDUSTRY AND INVESTOR EVENTS Ryvu will host partnering and investor meetings at all of the below conferences, with scientific presentations where noted: BIO-Europe Spring (Lisbon, Portugal), March 23-25 LSX World Congress (Lisbon, Portugal), March 24-25 AACR Annual Congress (San Diego, CA), April 17-22: Data to be presented on the ONCO Prime platform BIO Equity Europe (Prague, Czech Republic), May 4-6 ASCO Annual Meeting (Chicago, IL), May 29 to June 2 EHA Annual Congress (Stockholm, Sweden), June 12-15 BIO International Convention (San Diego, CA), June 22-25 2025 FISCAL YEAR FINANCIAL UPDATE Cash Position – On December 31, 2025, Ryvu Therapeutics held €25.5 million in cash, cash equivalents, and investment funds, compared to €52.7 million at the end of 2024. On March 9, 2026, the Company held €20.7 million in cash, cash equivalents and investment funds. In addition, Ryvu has secured approximately €20.9 million in non-dilutive grant funding. Operating Revenues – In 2025, Ryvu recognized total operating revenues (including grants) of €20.7 million, compared to €23.7 million in 2024. Operating costs, related primarily to research and development expenditures, excluding the valuation of NodThera shares and the non-cash cost of valuation of the Incentive Program for 2025, amounted to €43.0 million, compared to €51.1 million in 2024. EBITDA result – EBITDA loss for full-year 2025 was reduced to €23.2 million, compared to €25.9 million in the previous year. EBITDA loss in Q4 2025 was €3.5 million, compared to €8.8 million in the previous year. Net Loss Attributable to Common Shareholders – In 2025, the net loss attributable to common shareholders, excluding the non-cash cost of the Incentive Program, amounted to €23.2 million, compared to €24.9 million in the previous year. RYVU Therapeutics Leona Henryka Sternbacha 2 30-394 Kraków, Poland